MOST MAJOR IN VITRO DIAGNOSTICS (IVD) MANUFACTURERS started strong in 2022 as their base businesses regained steam and made up for the significant falloff in COVID-19 diagnostic test revenue. During first quarter 2022 earnings calls with investors, leaders at publicly traded IVD companies said clinical laboratories are interested in expanding test menus on technology platforms …
IVD Firms Grow During 2022, but COVID-19 Revenue Dropped Read More »
